Ashwagandha Commercial Master Dossier

High strategic premium potential with correspondingly high qualification and regulatory discipline.

Evidence chain

Botanical identity → correct plant part → controlled raw material → extraction process → marker specification → analytical method → contaminant control → destination/intended-use assessment.

Commercial doctrine

Do not sell a generic botanical story. Sell a documented ingredient whose identity and specification can survive buyer scrutiny. Premium pricing must be supported by evidence.

Risk

Regulatory treatment may differ by jurisdiction and intended use. No market entry should rely on assumptions transferred from another country.